Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

GILEAD SCIENCES, INC. (GILD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock ...